Manage patients with HCC  Continue HCC surveillance schedule for high‐risk subjects; 2‐month delay is acceptable
Document discussion of risks and benefits of delaying surveillance with patient
Proceed with HCC treatments as appropriate  Continue therapy for non‐COVID‐19 patients
For patients with HCC with COVID‐19, postpone elective transplant and resection surgery, withhold immunotherapy  Maintain care per guidelines
Admit early if COVID‐19 is diagnosed
Consider postponing HCC therapies